ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• Addressing Glass Particulates In Injectable Drug Formulations

  Learn how a new vial design that is capable of reducing the propensity for glass particulate generation on filling lines is enabling a significant, positive impact on product quality and safety.

• Platform Reduces Product Development Time And Cost By 30%

  Using innovative capsule-filling equipment and processing technology, and mini-tablet and drug-layered beadlet manufacturing, you can have an adaptable, easily modified formulation.

• Bringing A Biosimilar For Oncology To Market: Injectable Packaging From Early Development To Commercialization

  While in their early-stage development of a mAb biosimilar for oncology treatment, a large biopharmaceuticals company sought a packaging recommendation: a stopper to maintain high-quality standards.

• Masking Bitter Drug Taste In Pediatric Formulations With Microcaps

  The challenge was developing a taste masked, convenient dosage formulation of a very bitter API for patients two-years old and older undergoing treatment of HIV infection.

• 5 Ways Pre-Filled Syringes Contribute To Better Patient Outcomes

  In our series on pre-filled syringes, we explore five key ways this delivery format is enhancing patient outcomes, not just through the medicine it contains, but through the device design itself.

• How DFM Promotes Scalability, Repeatability, And Profitability

  Find out why it is critical that OEMs see and understand the benefits of taking time to build a mold or create automation more robustly to achieve long-term savings and higher annual production.

• Ophthalmic Drug Delivery

  Explore the challenges to effective delivery of drugs to the eye, intricacies of ophthalmic drug delivery, and advantages of nanoparticles as an enabling technology for ocular drug-delivery systems.

• Simultaneous Spray Drying For Combination Dry Powder Inhaler Formulations

  Three combination case studies are demonstrated, in which bevacizumab is paired with erlotinib, cisplatin, or paclitaxel in a dry powder inhaler formulation.

• Selecting Container Closure Components: A Data-Driven Approach To CCI

  Discover an efficient, data-driven process that employs innovative methods to accelerate the selection of a closure containment system that meets the requirements of the modern regulatory landscape.

• Strategies For Accelerating The Development Of Modified Release Oral Forms

  Careful selection of appropriate excipients and delivery technologies is key to the design of modified release (MR) formulations fulfilling specific performance requirements.